Art. -Nr.: HY-P9911

Biologically Validated

Vedolizumab

Name: Vedolizumab
Brand: MedChemExpress
SKU: HY-P9911
Price: 250.00 USD
Availability: InStock
Rating: 5 (3 reviews)

(Synonyms: Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002)

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.90%
CAS. Nr.: 943609-66-3
Molecular Weight:146.868 kDa

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Vedolizumab Chemical Structure

CAS. Nr.: 943609-66-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Isotype
- Recommend Isotype Controls
- Species Reactivity
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
- Gene ID
- Accession
- Conjugated
- Reconsititution
- Format
- Anwendung
- Verified Bioactivity
Chemical Information
Publications (3)
Protokoll
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

Isotype

Human IgG1 kappa

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

Integrin a4b7

Alle Integrin Isoform-spezifische Produkte anzeigen :

In Vitro

Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC₅₀=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC₅₀=0.02-0.06 μg/mL) and fibronectin (IC₅₀=0.02 μg/mL), but not vascular cell adhesion molecule 1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Gene ID

3676 [NCBI] & 3695 [NCBI]

Accession

P13612 & P26010

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Format

Human IgG1 kappa

Anwendung

ELISA, FACS, Functional assay

Verified Bioactivity

Flow cytometric analysis of 1X10⁶ Jurkat cells with Vedolizumab (HY-P9911, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Immobilized Human Integrin alpha 4 beta 7 Protein (His Tag) can bind Vedolizumab. The EC₅₀ for this effect is 119.52 ng/mL.

Chemical Information

CAS. Nr. 943609-66-3
Appearance Liquid
Molecular Weight 146.868 kDa
Color Colorless to light yellow
SMILES

[Vedolizumab]
Synonyms

Anti-Human lymphocyte α4β7 integrin, Humanized Antibody; LDP-02; MLN-002
Versand

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (3)

All In Vivo Efficacy StudyBio/Physico-chemical AssayHistological Imaging/StainingELISA

Sort by:

Journal Impact Factor

Adv Mater

Probiotics Bi-Enzymatic Cascade Repair System for Editing the Inflammatory Microenvironment to Boost Probiotic Therapy in Inflammatory Bowel Disease. [Abstract]

2025 Jan;37(4):e2412429. PMID: 39641224

Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]

Vedolizumab (5 mg/kg; i.v.; once every two days) decreased MPO levels in DSS-treated mice.

Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]

Vedolizumab (5 mg/kg; i.v.; once every two days for 10 d) effectively repaired pathological damage in the colonic tissues of IBD mice.

Vedolizumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jan;37(4):e2412429. [Abstract]

Vedolizumab (5 mg/kg; i.v.; once every two days for 10 d) significantly decreased colonic TNF-α, IL-6, and IL-1β levels in IBD mice.
Brain Behav Immun

Pro-inflammatory macrophages contribute to developing comorbid anxiety-like behaviors through gastrointestinal vagal afferent signaling in experimental colitis mice. [Abstract]

2025 May 8:128:620-633. PMID: 40348137

Vedolizumab purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2025 May 8:128:620-633. [Abstract]

Vedolizumab (30-50 mg/kg; i.p.; 4 d) significantly reduced the disease activity index of DSS-induced colitis mice.

Vedolizumab purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2025 May 8:128:620-633. [Abstract]

Vedolizumab (30-50 mg/kg; i.p.; 4 d) significantly reduced histological damage of colon tissues of DSS-induced colitis mice.
Anal Chim Acta

Calibration for quantitative Fc-glycosylation analysis of therapeutic IgG1-type monoclonal antibodies by using glycopeptide standards. [Abstract]

2021 Apr 15:1154:338306. PMID: 33736796

Protokoll

Kinase Assay^[1]

Vedolizumab inhibition of high-affinity binding of MAdCAM-1 to human peripheral blood memory CD4+ T lymphocytes is tested. Peripheral blood (90 μL) is incubated with a saturating concentration (3 μg/mL) of MAdCAM-1-murine-Fc fusion protein and 4 mM MnCl₂ in a final volume of 100 μL for 1 h at room temperature, in the presence or absence of vedolizumab. After washing with assay buffer, the cells are stained with fluorescentlabeled anti-mouse IgG for 15 min at room temperature. After washing again, cells are incubated with mouse serum for 10 min at room temperature, followed by staining with anti-CD4 and anti-CD45RO antibodies for 15 min at room temperature. After washing, red blood cells are lysed with BD FACS lysing solution and analyzed by flow cytometry in a FACSCalibur with CellQuest Pro software^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (263 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. [Content Brief]

[2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

Vedolizumab

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Vedolizumab

Natalizumab

Etrolizumab

Infliximab

Ustekinumab

Abrilumab

Adalimumab

Natalizumab (Anti-CD49d)

Guselkumab

Risankizumab

Human IgG1 kappa, Isotype Control

Mirikizumab

Vedolizumab (anti-α4β7-integrin)

Publications Citing Use of MedChemExpress (MCE) Vedolizumab

Alle Integrin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Protokoll

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Bioz

Vedolizumab

Natalizumab

Etrolizumab

Infliximab

Ustekinumab

Abrilumab

Adalimumab

Natalizumab (Anti-CD49d)

Guselkumab

Risankizumab

Human IgG1 kappa, Isotype Control

Mirikizumab

Vedolizumab (anti-α4β7-integrin)

Publications Citing Use of MedChemExpress (MCE) Vedolizumab

Alle Integrin Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Protokoll

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Vedolizumab Related Classifications

HY-P9911 Related Classifications

Bioz